Title : Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma.

Pub. Date : 2015 Mar

PMID : 25655379






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Siltuximab, a chimeric monoclonal antibody with high affinity and specificity for interleukin-6, has been shown to enhance anti-multiple myeloma activity of bortezomib and corticosteroid in vitro. Bortezomib interleukin 6 Homo sapiens